
Top Research Reports for Eli Lilly, Netflix & GE Aerospace
LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs.
Pfizer expects $1 billion net IRA impact in 2025, with $1.5 billion in losses and $500 million in gains due to Medicare Part D changes. BofA holds Pfizer's price target at $27, with 2025 EPS and sales projections largely unchanged from earlier forecasts.
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
In a public post in May, I wrote about Sana Biotechnology, Inc. SANA, a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since. Functional-cure potential. Sana's hypo-immune ( HIP ) edits let donor islet cells make insulin without triggering ...
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Cramer recommends buying NXP Semiconductors on Monday morning. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.
What's better than a great dividend? A great dividend that's growing.Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare stocks. Here's why they picked Abbott Laboratories ( NYSE: ABT ) , AbbVie ( NYSE: ABBV ) , and Eli ...
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to "benefit" from the levies.
Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Eli Lilly ( NYSE: LLY ) and Novo Nordisk ( NYSE: NVO ) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leaders in the GLP-1 weight loss space, and have been generating strong growth in recent years.But while they are ...
In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.
BofA updates Lilly's Q2 revenue and EPS forecast up on stronger Zepbound sales Analysts project Q2 earnings of $5.56 a share on $14.4 billion in sales Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Eli Lilly and Co. LLY is set to release its second-quarter earnings on ...
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Modified Kisunla dosing cut ARIA-E risk by 41% at 24 weeks and 35% at 52 weeks. Amyloid plaque reduction remained similar: 67% ( modified ) vs. 69% ( original ) at 24 weeks. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On The U.S.
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
STEP UP trial showed 21% average weight loss with 7.2 mg Wegovy; one-third lost at least 25% of body weight. Semaglutide 7.2 mg safety was in line with the 2.4 mg dose, though slight risk increase noted vs. placebo. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
WeightWatchers named Dr. Kim Boyd as Chief Medical Officer to lead clinical strategy and innovation. A new menopause-focused program launches this year, targeting women's health through clinical care and coaching.
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
SBC Medical Group Holdings Inc. SBC, a global franchise and provider of services for aesthetic clinics, is making inroads on the investor front, recently being added to the broad-market Russell 3000® Index. As of the close of trading on June 30, SBC Medical Group was part of the 2025 Russell ...
Image source: Getty Images.If you spend much time perusing the stocks that Wall Street analysts expect to produce eye-popping returns, you may have noticed a common theme: There's usually a ton of risk involved.If you'd prefer a portfolio that can outperform the overall market without taking ...
When you think of a great dividend stock to own, you're probably thinking of one that yields a high rate of return. But focusing on yield alone can be a mistake. It can lead you down a path where you buy a stock with a risky payout, and you could overlook promising dividend stocks simply because ...
Eli Lilly LLY has outperformed the market over the past 10 years by 12.75% on an annualized basis producing an average annual return of 24.16%. Currently, Eli Lilly has a market capitalization of $693.38 billion.
Hims & Hers shares have fallen 18% in the past month following Novo Nordisk's decision to end their partnership. Analysts expect a 2-3 year legal battle over compounded GLP-1 drugs, with no immediate injunction likely.
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.Three Motley Fool contributors think they've found no-brainer stocks to buy this month. Here's why they picked healthcare stocks AbbVie ( NYSE: ABBV ) , Eli Lilly ( NYSE: LLY ) ...
Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for ...
Alphabet Inc.'s GOOG GOOGL Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing.
For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend ( if it pays one ) , and maintains strong growth prospects.
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
These companies are poised to produce fireworks for your portfolio over the coming years.
Wegovy's U.S. launch price exceeded $1,300/month, $350 more than Ozempic. Eli Lilly's Zepbound surpassed Wegovy in weekly prescriptions in 2025. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add ...
The S&P 500 index faced its share of turmoil earlier this year, even temporarily slipping into bear territory amid concerns about the economy ahead. Investors worried that President Trump's import tariff plan would hurt the spending power of consumers and businesses -- and damage companies' ...
The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies are now trying to make waves in this space.But there is one company that's almost certain to dominate it at least through the end of the decade, and that's Eli Lilly ( NYSE: ...
BALA CYNWYD, Pa., June 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.